Adult Dosing
Chronic eczematous external otitis
- Instill 5 gtt into the affected ear(s) using the supplied ear-dropper bid x 1-2 wks
Note:
- Recommended for external ear use only; do not use occlusive dressings
Pediatric Dosing
Chronic eczematous external otitis
- Children
2yrs - Instill 5 gtt into the affected ear(s) using the supplied ear-dropper bid x 1-2 wks
Note:
- Recommended for external ear use only; do not use occlusive dressings
[Outline]
See Supplemental Patient Information
- Withdrawal of therapy may be associated with hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency. Manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria can also occur during therapy due to systemic absorption of topical corticosteroid
- Avoid application of potent topical steroids over large surface areas during prolonged use and addition of occlusive dressings, as these may augment systemic absorption. Periodically evaluate patients for evidence of HPA axis suppression by performing the urinary free cortisol and ACTH stimulation tests
- Withdraw the drug, reduce the frequency of application, or substitute a less potent steroid, on occurrence of HPA axis suppression. On discontinuation of topical corticosteroids, there is prompt and complete recovery of HPA axis function
- Signs and symptoms of glucocorticoid insufficiency may occur, requiring supplemental systemic corticosteroids
- Pediatric patients may be more susceptible to systemic toxicity from equivalent doses, as proportionally larger amounts of topical corticosteroids are absorbed
- Discontinue therapy on occurrence of irritation or hypersensitivity and provide appropriate therapy
- Immediately stop use and institute appropriate therapy on development of wheal and flare type reactions (which may be limited to pruritus) or other manifestations of hypersensitivity
- Appropriate antifungal or antibacterial agent should be initiated in the presence of concomitant dermatological infections. If a favorable response does not occur promptly, discontinue corticosteroid use until the infection has been adequately controlled
Cautions: Use cautiously in
- Hypersensitivity to peanuts
- Skin infections
- Pediatric patients
Supplemental Patient Information
- Advise patients to avoid using occlusive dressings
- Advise patients to avoid contact with the eyes. In case of contact, instruct patients to wash eyes liberally with water
- Inform patients to discontinue therapy when control is achieved; if no response is seen within 14 days, advise them to contact their physician
- Advise patients to avoid using this medication in disorders other than for which it was prescribed
- Instruct patients to promptly contact their physician if they experience any worsening of their skin condition
Pregnancy Category:C
Breastfeeding: Fluocinolone has not been studied during breastfeeding; short-term application of topical corticosteroids (fluocinolone) is not expected to pose a risk to the breastfed infant by passage into breast milk. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 11 April 2011). Manufacturer advises caution.
Pricing data from www.DrugStore.com in U.S.A.
- DermOtic 0.01 % OIL [Bottle] (HILL DERMACEUTICALS)
20 % = $39.4
60 % = $96.41 - Fluocinolone Acetonide 0.01 % OIL [Bottle] (AMNEAL PHARMACEUTICALS)
20 % = $35.99
40 % = $60.97
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
